Neuropsychological Assessment of Cognitive Impairment in Kidney Transplantation (NAsKiT) and its related risk factors: a study protocol

Hristos Karakizlis1 · Johanna M. Doerr2 · Anna Becker1 · Christian Nahrgang1 · Lucy Rainer1 · Ingolf Askevold3 · Juliane Liese3 · Winfried Padberg3 · Mostafa Aly4,5 · Rolf Weimer1 · Martin Juenemann2

Abstract

Background Association of cognitive impairment with chronic kidney disease has been reported over the last decade. Individuals show better cognitive performance after kidney transplantation than individuals on dialysis but are more likely to be affected by cognitive impairment than age-matched comparison groups. Better knowledge of the prevalence as well as course and profile of cognitive impairment is important for the design of future studies assessing the clinical impact of cognitive impairment and developing management strategies. The goal of our study is to examine the extent of cognitive impairment before and after transplantation and to derive a distinct profile of cognitive function using standard neurocognitive tests. Furthermore, we aim to assess whether transplantation per se leads to an improvement in cognitive performance.

Methods We are conducting a prospective single-center cohort study involving 100 kidney transplant individuals. Individuals who are wait-listed to receive a kidney transplantation or have already received one will be included in this study. Individuals will undergo a battery of detailed neurocognitive tests at baseline (in part before surgery), and then 3 and 12 months afterwards. Furthermore, the enrolled patients will complete a validated German version of the Cognitive Failure Questionnaire for self-assessment (s-CFQ) as well as the Hospital Anxiety and Depression Scale -Deutsche (HADS-D), a self-report screening instrument with two scales that capture anxiety and depression. In addition, a hair sample will be taken at each measurement time point for the determination of hair cortisol levels as a parameter for the cumulative hypothalamic-pituitary-adrenocortical axis activity over the previous three months. The primary outcome measure will be (a) the effect of kidney transplantation on the cognitive performance up to 12 months after transplantation and (b) the course of cognitive performance following kidney transplantation over time.

Discussion The results of our study have potentially important implications for the prevention and treatment of cognitive impairment in kidney transplant individuals. By increasing our knowledge of the neurocognitive profile and assigning the corresponding deficits, it might be possible to create an individualized training program to positively impact cognitive deficits in kidney transplant patients.

Keywords Kidney transplantation · Cognitive performance · Neuropsychological assessment · Depression · Cognitive profile · Chronic kidney disease
Abbreviations

sCFQ  Questionnaire for self-assessment
CKD  Chronic kidney disease
ESRD  End-stage renal disease
HADS-D  The German version of the Hospital Anxiety and Depression Scale
HPA  Hypothalamic-pituitary-adrenocortical
MCI  Mild cognitive impairment
MMSE  Mini-mental-state-Examination
NAsKiT  Neuropsychological Assessment of Cognitive Impairment in Kidney Transplantation
ROCFT  The Rey-Osterrieth Complex Figure Test
RWT  The “Regensburger Wortflüssigkeitstest
TMT  Trail Mark Test
VLMT  The “verbaler Lern- und Merkfähigkeitstest

Introduction

Kidney transplantation is the preferred therapy for individuals with end-stage renal disease (ESRD). To date, efforts to improve cardiovascular and metabolic parameters after transplantation have been made, but the cognitive aspects of chronic kidney disease (CKD) have been relatively overlooked. Association of cognitive impairment with CKD has been reported over the last decade [1–5]. Several studies suggested a prevalence of cognitive impairment in up to 80% of individuals with CKD [1, 2, 5–9]. It has been demonstrated that individuals showed better cognitive performance after kidney transplantation than dialysis individuals [10] but these individuals are also significantly more likely to be affected by cognitive impairment or dementia than age-matched comparison groups [11–13]. Additionally, kidney transplant recipients with cognitive impairment are also affected by increased mortality [14, 15]. However, the actual prevalence of cognitive impairment in transplant recipients (from deceased and living donor) is unknown. The development of cognitive functioning and the detailed degree (i.e., which cognitive domains are particularly affected) has not yet been well studied in kidney transplant individuals. Previous studies in individuals with end-stage renal disease have shown that executive functions are particularly affected [5].

Cognitive impairments are likely to imply a high individual loss of quality of life and early restriction of self-determination and of therapy adherence, which is highly necessary for treatment. Early detection is of paramount significance so as to take preventive action, assess illness-related grief, and to avoid misunderstandings during medical care [16].

Better knowledge of the prevalence as well as of the course and profile of cognitive impairment is important for designing future studies, which will assess the clinical impact of cognitive impairment and develop management strategies. A limited number of studies have concentrated on the effects of kidney transplantation on cognitive function with divergent results [13].

The goal of our study is to examine (a) the extent of cognitive impairment, (b) the course of cognitive performance in kidney transplant individuals and (c) the profile of cognitive impairment (i.e., if a certain cognitive domain is more affected than others). Furthermore, we explore the impact and temporal course of variables with a potential influence on cognitive performance as secondary research questions. In this context, variables related to stress (subjective stress, depression, and long-term activity of the hypothalamic pituitary adrenal axis (HPA)) are of special interest to us.

Materials and methods

Study design and enrollment

We are conducting a prospective single-center cohort study at the University Hospital Giessen and Marburg, Giessen, Germany. It complies with the Declaration of Helsinki and has been approved by the ethics committee of the Justus Liebig University Giessen (ref 195/20). Written informed consent will be signed by the individuals and by the investigator prior to the patient’s enrollment.

Our study team consists of members of the nephrology, kidney transplantation, neurology and neuropsychology departments.

Inclusion and exclusion criteria

Individuals who are scheduled to receive a kidney transplantation (immediate—deceased kidney donor, or within the following 2 weeks—living kidney donors) or have already received a kidney transplantation in the past will be included in this study. Due to the use of a standardized psychological assessment, individuals have to be native German speakers and at least 18 years of age. Individuals under the legal supervision of a caregiver and with preexisting psychiatric disorders will be excluded from the study.

The study is divided into two parts (Table 1).

Part A:

All included individuals undergo a detailed neuropsychological test battery on the day of transplantation (deceased kidney donation), or within 14 days before transplantation (living kidney donation). The neuropsychological test battery will be repeated after 3 and 12 months.

For individuals on the waiting list for deceased donor kidney transplantation we aspire to also carry out neuropsychological tests during standard visits to the hospital. Standard visits are typically several years apart and the date of transplantation is unforeseeable. Therefore, we expect not to be
able to gather respective data for the majority of our participants and rather, will use it descriptively and for qualitative analyses.

Part B:
All included individuals who have already undergone transplantation and are in outpatient follow-up will undergo the same neurocognitive test battery as individuals in part A at baseline, after 3 months, and after 12 months.

Neuropsychological assessment
A battery of standardized cognitive tests will be performed at different timepoints (Table 1). Parallel test forms will be used at follow-up to account for learning effects. The order in which the parallel test forms are presented will be counterbalanced so that each parallel test form will be administered with the same frequency at each test time point.

The cognitive test battery
We first administer the Mini-Mental Status Examination (MMSE) [17] as a neurocognitive screening test, together with a test battery consisting of five tests, assessing the cognitive domains of selective attention, verbal and visual memory with short-delay and long-delay memory conditions, verbal working memory, word fluency and symbol processing. Raw scores are transformed into z-scores adjusted for age, and if available sex, as well as years of education.

The individual’s degree of impairment will be stratified using the algorithm adopted by Murray and colleagues [1] based on the Mayo criteria for mild cognitive impairment (MCI) [18] and the Diagnostic and Statistical Manual, fifth Edition, criteria for major neurocognitive impairment as approximate guidelines [19].

| Table 1 | Trial schedule of enrollment and assessments |
|---------|------------------------------------------|
| Study Period, Part A | Enrollment | Post-allocation |
| Time point | $t_{-1}$ | $t_1$ | $t_2$ | $t_3$ |
| Enrollment | | | | |
| Eligibility screen | X | | | |
| Informed consent | X | | | |
| Allocation | X | | | |
| Interventions | | | | |
| Kidney transplantation | | | | X |
| Assessments | | | | |
| ROCFT | X | X | X | X |
| VLMT | X | X | X | X |
| TMT-A | X | X | X | X |
| WMS-R-numbers forward | X | X | X | X |
| TMT-B | X | X | X | X |
| WMS-R-numbers backwards | X | X | X | X |
| RWT | X | X | X | X |

Study period, Part B

| Time point | $t_{-2}$ | $t_{-1}$ | $t_1$ | $t_2$ |
| Enrollment | | | | |
| Eligibility screen | X | | | |
| Informed consent | X | | | |
| Allocation | X | | | |
| Interventions | | | | |
| Kidney transplantation | | | | X |
| Assessments | | | | |
| ROCFT | X | X | X | X |
| VLMT | X | X | X | X |
| TMT-A | X | X | X | X |
| WMS-R-numbers forward | X | X | X | X |
| TMT-B | X | X | X | X |
| WMS-R-numbers backwards | X | X | X | X |
| RWT | X | X | X | X |
1. Unimpaired: performance better than 1.5 standard deviations (SD) below the norm sample in any test considered for the classification.
2. Mildly impaired: mild deficits (scores 1.50 to 1.99 SD below the norm sample) in only one domain.
3. Moderately impaired: deficits in two domains or a severe deficit (2.0 SD below the norm sample) in one domain.
4. Severely impaired: deficits in at least two domains.

The domains of executive functions (semantic and phonemic fluency, working memory, and mental flexibility), verbal memory (immediate and delayed recall, recognition), visual memory (delayed recall), and attention (symbol processing speed) are considered in the classification.

For this purpose, we will use the following validated tests (Table 2):

**Verbal learning and memory test**
To assess verbal memory, the “verbal Lern- und Merkfähigkeitstest” (VLMT) [20], a modified German version of the Rey Auditory Verbal Learning Test [21] will be administered. This test can be used to evaluate short-term memory, learning, episodic memory and verbal discriminability. First, a list of 15 words is read to the patient by the investigator. The direct retrieval by the patient is scored as short-term memory performance. Second, the patient has to learn the word list in five learning trials. The sum of the recalled words represents a learning parameter. Third, a second word list with new words is presented verbally, and recalled only once for interference. After this, the learned words on the first word list have to be recalled. This is used as a measurement of a short-delayed function of verbal episodic memory. A second verbal episodic memory measurement is performed 20 min later (long delay). Finally, the verbal recognition ability is assessed by discriminating between already learned and new words. Between the short-delayed verbal episodic memory trial and the long-delayed verbal episodic memory trial, nonverbal cognitive tests are performed to avoid the potential effect of interfering words not included in the learned wordlist. Three parallel versions of this test are available and are implemented during baseline and follow-ups in alternating order.

**Rey-Osterrieth Complex Figure Test**
In the Rey-Osterrieth Complex Figure Test (ROCFT) [22], the subject is first asked to copy a complex figure (visuo-construction/action planning). After about 30 min, the subject is then asked to draw the figure again from memory (visual memory).

**Trail Making Test**
Selective attention and cognitive flexibility are examined using the Trail Making Test (TMT) [23]. It consists of subtests A and B. In TMT-A, the patient has to link numbers in ascending order as quickly as possible with a pencil (visual scanning and basal psychomotor speed, selective attention) on a test sheet. TMT-B additionally requires the ability of cognitive flexibility by switching between letters and numbers. The quotient formed from the processing time of subtest B and subtest A (B/A) can be used to represent a measure of cognitive switching ability (serial cognitive flexibility, executive function) independently of any psychomotor slowing.

**Wechsler Memory Scale (subtest digit span)**
The subject is instructed to repeat successively increasing sequences of numbers forward (memory span, attention) and backward (working memory, executive function) on the "digit span" subtest of the Wechsler Memory Scale—Revised (WMS-R) [24].

**Regensburg-word-fluency-test**
Semantic and phonemic verbal fluency will be tested using the “Regensburger Wortflüssigkeitstest” (RWT) [25] which also exists in parallel versions. In this test, the patient is asked to name as many words as possible that belong to a specific category (e.g. animals) within 1 min. For the phonemic word fluency subtest, the target is to name as many words as possible within 1 min that begin with a specific letter. This is a test for divergent thinking (executive function).

**Possible stress-related mediators and moderators**

**Anxiety and depression**
The HADS-D [26], the German version of the Hospital Anxiety and Depression Scale by Zigmond and Snaith will be administered [27]. It is a standardized self-report screening.
instrument with two scales that capture anxiety and depression. Each scale is represented by seven items presented alternately. Each item is scored on a four-point Likert scale. The questions measure the expression of anxious and depressive symptoms referring to the last week. The items of the anxiety scale mainly refer to symptoms such as worry, apprehension, nervousness, and motor tension. The items of the depression scale focus on loss of motivation and interest, reduction of joy, and reduced drive. The questionnaire is well suited for recording reactive disorders in the physically ill. Another advantage is the quick completion time of approximately five minutes.

Self-assessment of cognitive failure

Study individuals will complete a validated German version of the Cognitive Failure Questionnaire for self-assessment (s-CFQ) [28]. It represents a procedure for self-assessment of the frequency of committed everyday errors, in the areas of perception, memory, and action regulation (executive functions). The CFQ has been used, revised, extended, and validated in numerous studies [28, 29].

Stress experience

The Perceived Stress Scale [30] is used to assess subjective stress levels. With 10 items on a scale from “never” (0) to “very often” (4), the scale measures the occurrence of stress (feelings of being overtaxed, loss of control) in the last month. The German translation showed good internal consistency and construct validity [31].

We extended this questionnaire to include stress levels before and after testing prior to planned transplantation by the item “How stressed do you feel at the moment?” (1–10).

This allows us to measure the acute stress level at the beginning and at the end of the cognitive test and thus to investigate the difference in stress levels between the groups as well as the influence of the current stress level on cognitive functions.

Hair cortisol

A hair sample is taken from the included individuals at each measurement time point for the determination of hair cortisol. Two to three thin hair strands are cut as close to the scalp as possible at the position of the posterior vertex. This protocol has been used successfully in studies for over 10 years and is well accepted by study participants [32]. The strands are first preserved and then sent to the laboratory of the Clinical Psychology of Adulthood at the University of Vienna (Prof. Dr. U. M. Nater) for hair cortisol analysis. For the determination of cortisol, commercial immunoassays with chemiluminescent detection (CLIA) from IBL, Hamburg, Germany, are used. For hair cortisol, high test–retest reliability as well as positive correlations with cortisol values from other media (e.g., saliva and urine), and with subjective stress measures are shown [33]. Hair cortisol levels of the first three centimeters from the scalp can be considered a measure of cumulative HPA axis activity over the previous three months [34].

In order to check the influence of steroids on the HPA axis, steroid doses are documented in all patients. Patients do not receive cortisone until transplantation. During transplantation, patients receive a cortisone shot of 1 g prednisolone on the day of transplantation. At the time of discharge from the hospital, the maintenance dose is 10 mg. The dose is usually reduced by 2.5 mg every 3 months and patients are no longer administered cortisone after 12 months. Furthermore, unscheduled intake of cortisone (e.g., during rejection episodes) is documented.

Patient baseline data, comorbidity, laboratory parameters

In addition, baseline patient data, such as age, type of underlying disease, type and duration as well as the dose (Kt/V) of the dialysis therapy will be obtained. Comorbidities, that may have an impact on cognitive performance (such as previous stroke, coronary heart disease, hypertension, diabetes mellitus, existing dementia or depression), will be documented. Furthermore, blood parameters such as hemoglobin, creatinine, calcium, phosphorus, albumin, triglycerides, cholesterol, urea, pH-value, CO₂, and bicarbonate will be recorded. Current medication data will be obtained from the medical records and by self-report at each testing session. In addition, changes in medication are recorded. The examinations were executed by trained and certified medical students.

Statistical analysis

This is a within-group design with three measurement time points. We will investigate the proportion (percentage) of individuals that fulfill the above mentioned criteria at each given time point as estimates of prevalence of MCI and major neurocognitive impairment. Furthermore, we will conduct repeated-measures analysis of variance to investigate changes in cognitive performance over time, as well as the influence of different predictors. Cognitive performance of the individuals as a composite score and for each cognitive domain constitutes the dependent variables. The time of measurement and other control variables listed above represent the independent variables. A possible accumulation of the type I error is counteracted by an α-error correction (see below). The partial Eta-squared is calculated as the effect size, and the pairwise post-hoc comparisons are also
corrected for multiple comparisons. The requirement of normal distribution is evaluated by the Kolmogorov–Smirnov test. Variance homogeneity is checked by Levene’s test. If the prerequisites for parametric statistics are not fulfilled, a distribution assumption-free covariance analysis according to the Quade model with rank-transformed variables is performed as an alternative.

Further questions are evaluated in terms of exploratory data analysis. Group differences are assessed using the t-test for independent samples or the Mann–Whitney-U test, depending on the scale level. Panels with discrete characteristics are analyzed with the $\chi^2$-test. Measures of correlation for discrete variables represent the contingency coefficients. For continuous characteristics, correlation measures according to Pearson (product-moment correlation) or Spearman (rank correlation) are used depending on the data level, in exceptional cases also according to Kendall (rank correlation without equidistance assumption).

The global significance level is set at $\alpha = 0.05$. A false discovery rate (FDR) is calculated for $\alpha$-error correction in multiple comparisons [35]. In the stepwise procedure, $p$-values are ranked in descending order; the null hypothesis is rejected if:

$$p(i) \leq \frac{i \cdot \alpha}{m}$$

where $m$ represents the number of $p$ values and $i$ the rank of the $p$ value. Assuming $i = 1$, the FDR is equivalent to the Bonferroni correction.

**Sample size calculation**

In order to investigate the prevalence of MCI or dementia, all individuals currently registered on the local transplant list, who are able to consent and agree to participate in the study, will be included. Currently, this list includes 142 individuals (75 individuals are in status T (transplantable), 67 individuals are in status NT (non-transplantable).

With regard to outcome measures, previous studies have shown highly significant improvements in some domains after transplantation [36], but have not reported effect sizes or statistical parameters that could be used to calculate effect sizes. Harciarek and colleagues [37, 38] report moderate to strong “time × comparison with healthy controls” interaction effects. We therefore conservatively expect to find low to medium effect sizes. For the detection of low to medium ($f = 0.20$) within-person effects with 3 measurement time points and 2 groups using a repeated-measures ANOVA as explained above, a power ($1 - \beta$) (type II error probability) of 0.80 and a type-I error probability ($\alpha$) of 0.05, a sample size of 42 is necessary [39, 40]. We therefore aim for a sample size of 50 persons for the follow-up measurements.

**Primary outcome measure**

The primary outcome measure will be cognitive performance. (a) We will compare cognitive performance before and after kidney transplantation, up to 12 months after transplantation in a population of patients who did not yet receive kidney grafts before enrollment in the study (part A) and (b) we will also investigate the development of cognitive performance over a period of 12 months in a population of patients who already received kidney grafts before enrollment in the study (part B).

**Secondary outcome measures**

As a secondary outcome, we will assess a distinct profile of cognitive function using standard neurocognitive tests. Furthermore, we will explore the impact and temporal development of a set of risk factors for deficits in cognitive performance. Second, we want to examine the extent to which cognitive impairment affects depression at all follow-up time points. Third, we want to assess how stressors negatively or positively affect cognitive performance. Fourth, we want to investigate to what degree cognitive performance affects the formation and development of donor-specific antibodies.

**Discussion**

The purpose of this study is to assess the extent and development of cognitive impairment in kidney transplant individuals and to provide a clear profile of cognitive function using standardized neurocognitive tests. Furthermore, we aim to evaluate whether transplantation per se leads to an improvement in cognitive performance.

There is currently no standardized test battery for kidney transplant populations, so we selected different validated tests to evaluate the different domains. Through this, it will be possible to create a neurocognitive profile of the investigated population. The tests used in kidney transplant individuals [10, 11, 41, 42] (Brief Cognitive State Examination, MoCA und 3MS, Modified Mini-Mental State Examination), which can be found in literature, are only screening tests and may underestimate the extent of cognitive impairment. We use a more comprehensive neurocognitive test battery, which is then also able to establish a neurocognitive profile in individuals after kidney transplantation. A recently published study showed a high prevalence of cognitive impairment in dialysis individuals [5], examined by the CERAD Test battery [43].

Anemia, secondary hyperparathyroidism, dialysis disequilibrium and uremic toxins (UT) have been reported as major causes of cognitive impairment accompanied by chronic kidney disease [44], as well as dialysis duration [45].
We assume that these parameters improve after transplantation and want to investigate the effect of these parameters on cognitive function.

Depression in hemodialysis individuals is characterized as one of the most common psychological aspects regarding studies on individuals with kidney failure [46]. To evaluate the frequency of depression and its effect on cognitive performance the HADS-D [26] Test will be performed. We also hypothesize that transplanted individuals suffering from depression display significantly higher cognitive impairment than transplanted individuals without depression. In one of our previous investigations, depression was significantly associated with a lower level of cognition [5]. Other studies have also found similar decline in cognition with the presence of depression [45, 47, 48]. This can be explained by the effects of symptoms of depression on domains of cognition like executive functioning and processing speed [48, 49]. A recent meta-analysis also shows that subjective stress influences the development of cognitive impairment [50].

A likely mediator of the association between stress and cognitive performance, but also between depression and cognitive performance, is HPA axis activity, which is commonly assessed via its end-product cortisol. Excess cortisol has been found to have damaging effects on the limbic system, which leads to impairment of learning mechanisms [51]. Some studies also suggest that higher cortisol levels are associated with slower processing speed in persons suffering from depression [52, 53]. In line with this, one study found a negative association between hair cortisol and cognitive performance after stroke [54]. Hair cortisol as a marker of HPA axis activity is of special interest because it represents the cumulative HPA axis activity of the months before the time point of measurement [33] (in our case, before kidney transplant). However, we are not aware of any study that has investigated associations of subjective stress or hair cortisol, or their interaction with depression, in kidney transplant individuals.

Individuals who received kidneys from a deceased donor as well individuals who received living kidney donation will be investigated. In order to detect an effect of transplantation, testing will be performed close to the time of transplantation. Neurocognitive testing is performed in living kidney donor recipients within 14 days prior to planned transplantation. In individuals receiving postmortem donation, prior scheduling of neurocognitive testing is not possible. After individuals are placed on the waiting list, the waiting period for a deceased donor renal transplant usually ranges between 6 to 8 years in Germany [55] and around 4 years in the Eurotransplant region [56], making testing at listing impractical. Therefore, we decided to perform testing when we admit individuals for kidney transplantation during dialysis prior to transplantation. It has been shown that the test results are not affected by dialysis [57].

Despite vigorous planning, the present investigation certainly contains some limitations. The test environment may not be optimal for the individuals who will receive the kidney from a deceased donor (patient might be more nervous than usual). It would have been more ideal to test those individuals 1 or 2 weeks before transplantation, but this is not possible, as it is not known when these individuals will receive their transplant offers. It seems possible that HADS responses may be influenced by the positive news of the transplantation. Here, however, it is likely that the influence might be more pronounced in individuals for whom transplantation is not planned (deceased donor kidney transplantation) than in those for whom transplantation is planned (living donation).

The results of our study could have potentially important implications for the prevention and treatment of cognitive impairment in kidney transplant individuals. By increasing our knowledge of the neurocognitive profile and assigning the corresponding deficits, it might be possible to create an individualized training program to positively impact cognitive deficits in these individuals.

**Trial status**

The study is currently enrolling individuals. The local human research ethics committee of the Justus-Liebig-University of Giessen (AZ 195/20) approved this study. Recruitment started in Jan 2021 and is expected to be completed in December 2022. The study was registered with the German clinical Trials register under the number DRKS00029164.

**Funding** Open Access funding enabled and organized by Projekt DEAL. None.

**Availability of data and material** The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

**Code availability** No new code was produced in this study.

**Declarations**

**Conflict of interest** Each author certifies that he or she, or a member of their immediate family, has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the contents of the submitted article. The results presented in this article have not been published previously in whole or part, except in abstract format.

**Ethical approval and consent to participate** This study was approved by the ethics committee of the University of Giessen and conforms to
the Declaration of Helsinki. Written informed consent is obtained from all the participants prior to study enrollment.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Murray AM, Tupper DE, Knopman DS, Gilbertson DT, Pederson SL, Li S et al (2006) Cognitive impairment in hemodialysis patients is common. Neurology 67:216–223
2. Griva K, Stygall J, Hankins M, Davenport A, Harrison M, Newman SP (2010) Cognitive impairment and 7-year mortality in dialysis patients. Am J Kidney Dis 56:693–703
3. Fazekas G, Fazekas F, Schmidt R, Kapeller P, Offenbacher H, KrejzGI (1995) Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment. J Neurol Sci 134:83–88
4. Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R et al (2008) Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am J Kidney Dis 52:227–234
5. Karakizlis H, Bohli K, Ziemek J, Dodel R, Hoyer J (2021) Assessment of cognitive impairment and related risk factors in hemodialysis patients. J Nephrol. https://doi.org/10.1007/s40620-021-01170-3
6. Kurella M, Chertow GM, Fried LF, Cummings SR, Harris T, Simonsick E et al (2005) Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 16:2127–2133
7. Dasgupta I, Patel M, Mohammed N, Baharani J, Subramanian T, Thomas GN et al (2018) Cognitive function declines significantly during haemodialysis in a majority of patients: a call for further research. Blood Purif 45:347–355
8. Seidel UK, Gronewold J, Vossek M, Todica O, Kribben A, Bruck H et al (2014) The prevalence, severity, and association with HbA1c and fibrinogen of cognitive impairment in chronic kidney disease. Kidney Int 85:693–702
9. van Zwieten A, Wong G, Ruospo M, Palmer SC, Barulli MR, Irurillo A et al (2018) Prevalence and patterns of cognitive impairment in adult hemodialysis patients: the COGNITIVE-HD study. Nephrol Dial Transpl 33:1197–1206
10. Ozcan H, Yucel A, Avsar UZ, Cankaya E, Yucel N, Gozubuyuk H et al (2015) Kidney transplantation is superior to hemodialysis and peritoneal dialysis in terms of cognitive function, anxiety, and depression symptoms in chronic kidney disease. Transpl Proc 47:1348–1351
11. Gupta A, Mahnken JD, Johnson DK, Thomas TS, Subramaniam D, Polshak T et al (2017) Prevalence and correlates of cognitive impairment in kidney transplant recipients. BMC Nephrol 18:158
12. Gupta A, Montgomery RN, Bedros V, Lesko J, Mahnken JD, Chakraborty S et al (2019) Subclinical cognitive impairment and listing for kidney transplantation. Clin J Am Soc Nephrol 14:567–575
13. Van Sandwijk MS, Ten Berge IJ, Majoie CB, Caan MW, De Sonneville LM, Van Gool WA et al (2016) Cognitive changes in chronic kidney disease and after transplantation. Transplantation 100:734–742
14. McAdams-DeMarco MA, Bae S, Chu N, Gross AL, Brown CHT, Oh E et al (2017) Dementia and Alzheimer’s disease among older kidney transplant recipients. J Am Soc Nephrol 28:1575–1583
15. Sharma A, Yabes J, Al Mawed S, Wu C, Stilley C, Unruh M et al (2016) Impact of cognitive function change on mortality in renal transplant and end-stage renal disease patients. Am J Nephrol 44:462–472
16. Murray AM, Knopman DS (2010) Cognitive impairment in CKD: no longer an occult burden. Am J Kidney Dis 56:615–618
17. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
18. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308
19. American-Psychiatric-Association (1987) Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press, Washington
20. Helmstaedter C, Lendt M, Lux S (2001) Verbal Lern- und Merkfähigkeitstest (VLMT). Beltz Test, Göttingen
21. Strauss ESE, Spreen O (2006) A compendium of neuropsychological tests: administration, norms and commentary, 3rd edn. University Press, Oxford
22. Shin MS, Park SY, Park SR, Seol SH, Kwon JS (2006) Clinical and empirical applications of the Rey-Osterrieth Complex Figure Test. Nat Protoc 1:892–899
23. Tomaugh TN (2004) Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 19:203–214
24. Hääting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J (2000) Wechsler Memory Scale revised, deutsche Version. Hogrefe, Göttingen
25. Aschenbrenner S, Tuchta O, Lange KW (2001) Regentsburger Wortflüssigkeits-Test. Hogrefe, Göttingen
26. Herrmann-Lingen CBU, Snaith RP (2011) Hospital anxiety and depression scale: HADS-D; german version. Huber, Bern
27. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370
28. Klumb PL (1995) Cognitive failures and performance differences: validation studies of a German version of the cognitive failures questionnaire. Ergonomics 38:1456–1467
29. Wallace JC, Kass SJ, Stanny CJ (2002) The cognitive failures questionnaire revisited: dimensions and correlates. J Gen Psychol 129:238–256
30. Cohen S, Kamarck T, Mermelstein R (1983) A global measure of perceived stress. J Health Soc Behav 24:385–396
31. Klein EM, Braehler E, Dreier M, Reinecke L, Muller KW, Schmutzer G et al (2016) The German version of the Perceived Stress Scale - psychometric characteristics in a representative German community sample. BMC Psychiatry 16:159
32. Kirschbaum C, Tietze A, Skoluda N, Dettenborn L (2009) Hair cortisol incorporation into hair in the third trimester of pregnancy. Psychoneuroendocrinology 34:32–37
33. Stalder T, Kirschbaum C (2012) Analysis of cortisol in hair: a retrospective calendar of cortisol production. Psychoneuroendocrinology 37:40620-021-01170-3
34. Staufenbiel SM, Penninx BW, Spijker AT, Elzinga BM, van Rossum EF (2013) Hair cortisol, stress exposure, and mental health
35. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57:289–300

36. Kaya Y, Ozturkeri OA, Benli US, Colak T (2013) Evaluation of the cognitive functions in patients with chronic renal failure before and after renal transplantation. Acta Neurol Belg 113:147–155

37. Harciarek M, Biedunkiewicz B, Lichodziejewska-Niemiernko M, Debska-Slizien A, Rutkowski B (2009) Cognitive performance before and after kidney transplantation: a prospective controlled study of adequately dialyzed patients with end-stage renal disease. J Int Neuropsychol Soc 15:684–694

38. Harciarek M, Biedunkiewicz B, Lichodziejewska-Niemiernko M, Debska-Slizien A, Rutkowski B (2011) Continuous cognitive improvement 1 year following successful kidney transplant. Kidney Int 79:1353–1360

39. Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191

40. Faul F, Erdfelder E, Buchner A, Lang AG (2009) Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41:1149–1160

41. Thomas AG, Ruck JM, Shaffer AA, Haugen CE, Ying H, Warsame F et al (2019) Kidney transplant outcomes in recipients with cognitive impairment: a national registry and prospective cohort study. Transplantation 103:1504–1513

42. Chu NM, Gross AL, Shaffer AA, Haugen CE, Norman SP, Xue QL et al (2019) Frailty and changes in cognitive function after kidney transplantation. J Am Soc Nephrol 30:336–345

43. Chandler MJ, Lacritz LH, Hynan LS, Barnard HD, Allen G, Deschner M et al (2005) A total score for the CERAD neuropsychological battery. Neurology 65:102–106

44. Watanabe K, Watanabe T, Nakayama M (2014) Cerebro-renal interactions: impact of uremic toxins on cognitive function. Neuropsychology 44:184–193

45. Joseph SJ, Bhandari SS, Dutta S (2019) Cognitive impairment and its correlates in chronic kidney disease patients undergoing haemodialysis. J Evol Med Dent Sci 8:2818–2822

46. Andrade RCS (2012) Depression in chronic kidney disease and haemodialysis patients. Psychology 3:974–978

47. Jung S, Lee YK, Choi SR, Hwang SH, Noh JW (2013) Relationship between cognitive impairment and depression in dialysis patients. Yonsei Med J 54:1447–1453

48. Agganis BT, Weiner DE, Giang LM, Scott T, Tighiouart H, Griffith JL et al (2010) Depression and cognitive function in maintenance hemodialysis patients. Am J Kidney Dis 56:704–712

49. Crowe K, Quinn TJ, Mark PB, Findlay MD (2021) “Is it removed during dialysis?” Cognitive dysfunction in advanced kidney failure-a review article. Front Neurol 12:787370

50. Franks KH, Bransby L, Saling MM, MP (2021) Association of stress with risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. J Alzheimers Dis 82:1573–1590

51. Herbert J, Goodyer IM, Grossman AB, Hastings MH, de Kloet ER, Lightman SL et al (2006) Do corticosteroids damage the brain? J Neuroendocrinol 18:393–411

52. Gomez RG, Posener JA, Keller J, DeBattista C, Solvason B, Schatzberg AF (2009) Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. Psychoneuroendocrinology 34:1012–1018

53. Hinkelmann K, Moritz S, Botzenhardt J, Riedesel K, Wiedemann K, Kellner M et al (2009) Cognitive impairment in major depression: association with salivary cortisol. Biol Psychiatry 66:879–885

54. Ben Assayag E, Tene O, Korczyn AD, Shopin L, Auriel E, Molad J et al (2017) High hair cortisol concentrations predict worse cognitive outcome after stroke: Results from the TABASCO prospective cohort study. Psychoneuroendocrinology 82:133–139

55. Deutsche-Stiftung-Organtransplantation. Jahresbericht Organ- spende und Transplantation (2019); pp 1–120. https://www.dso.de/SiteCollectionDocuments/DSO-Jahresbericht%202019.pdf. Accessed 25 Sept 2020

56. Eurotransplant-Community T. Annual Report (2019); pp 1–87. https://www.eurotransplant.org/wp-content/uploads/2020/06/Annual-Report-2019.pdf. Accessed 25 Sept 2020

57. Karakizlis H, Thiele S, Greene B, Hoyer J (2021) Cognitive performance in dialysis patients - “when is the right time to test?” BMC Nephrol 22:205

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.